Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer

Elisa Fontana, Francesca Pucci, Roberta Camisa, Simona Bui, Salvatore Galdy, Francesco Leonardi, Francesca Virginia Negri, Elisa Anselmi, Pier Luigi Losardo, Luigi Roncoroni, Paolo Dell'Abate, Pellegrino Crafa, Stefano Cascinu, Andrea Ardizzoni

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5- fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC). Patients and Methods: Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m2 weekly and 5-fluorouracil 200 mg/m 2/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points. Results: Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7% (95% confidence interval=7.7-25.7%). After a median follow-up of 73.5 months, 23 patients (34.8%) had experienced relapse. Five-year actuarial RFS and OS rates were 64% and 73%, respectively. Five-year actuarial RFS was 91.7% in the ypCR group versus 57.8% in non-ypCR cases. Conclusion: Long-term local control and survival after this very well-tolerated regimen appear encouraging.

Original languageEnglish
Pages (from-to)725-730
Number of pages6
JournalAnticancer Research
Volume33
Issue number2
Publication statusPublished - Feb 2013

Fingerprint

oxaliplatin
Rectal Neoplasms
Fluorouracil
Survival
Recurrence
Therapeutics
Safety
Diarrhea
Adenocarcinoma
Radiotherapy
Survival Rate

Keywords

  • Chemoradiation
  • Colorectal adenocarcinoma
  • Combined treatment
  • Long-term outcome.
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fontana, E., Pucci, F., Camisa, R., Bui, S., Galdy, S., Leonardi, F., ... Ardizzoni, A. (2013). Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. Anticancer Research, 33(2), 725-730.

Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. / Fontana, Elisa; Pucci, Francesca; Camisa, Roberta; Bui, Simona; Galdy, Salvatore; Leonardi, Francesco; Negri, Francesca Virginia; Anselmi, Elisa; Losardo, Pier Luigi; Roncoroni, Luigi; Dell'Abate, Paolo; Crafa, Pellegrino; Cascinu, Stefano; Ardizzoni, Andrea.

In: Anticancer Research, Vol. 33, No. 2, 02.2013, p. 725-730.

Research output: Contribution to journalArticle

Fontana, E, Pucci, F, Camisa, R, Bui, S, Galdy, S, Leonardi, F, Negri, FV, Anselmi, E, Losardo, PL, Roncoroni, L, Dell'Abate, P, Crafa, P, Cascinu, S & Ardizzoni, A 2013, 'Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer', Anticancer Research, vol. 33, no. 2, pp. 725-730.
Fontana E, Pucci F, Camisa R, Bui S, Galdy S, Leonardi F et al. Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. Anticancer Research. 2013 Feb;33(2):725-730.
Fontana, Elisa ; Pucci, Francesca ; Camisa, Roberta ; Bui, Simona ; Galdy, Salvatore ; Leonardi, Francesco ; Negri, Francesca Virginia ; Anselmi, Elisa ; Losardo, Pier Luigi ; Roncoroni, Luigi ; Dell'Abate, Paolo ; Crafa, Pellegrino ; Cascinu, Stefano ; Ardizzoni, Andrea. / Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. In: Anticancer Research. 2013 ; Vol. 33, No. 2. pp. 725-730.
@article{831292d705d04432a20d8622eb6faafa,
title = "Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer",
abstract = "Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5- fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC). Patients and Methods: Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m2 weekly and 5-fluorouracil 200 mg/m 2/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points. Results: Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7{\%} (95{\%} confidence interval=7.7-25.7{\%}). After a median follow-up of 73.5 months, 23 patients (34.8{\%}) had experienced relapse. Five-year actuarial RFS and OS rates were 64{\%} and 73{\%}, respectively. Five-year actuarial RFS was 91.7{\%} in the ypCR group versus 57.8{\%} in non-ypCR cases. Conclusion: Long-term local control and survival after this very well-tolerated regimen appear encouraging.",
keywords = "Chemoradiation, Colorectal adenocarcinoma, Combined treatment, Long-term outcome., Neoadjuvant therapy",
author = "Elisa Fontana and Francesca Pucci and Roberta Camisa and Simona Bui and Salvatore Galdy and Francesco Leonardi and Negri, {Francesca Virginia} and Elisa Anselmi and Losardo, {Pier Luigi} and Luigi Roncoroni and Paolo Dell'Abate and Pellegrino Crafa and Stefano Cascinu and Andrea Ardizzoni",
year = "2013",
month = "2",
language = "English",
volume = "33",
pages = "725--730",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer

AU - Fontana, Elisa

AU - Pucci, Francesca

AU - Camisa, Roberta

AU - Bui, Simona

AU - Galdy, Salvatore

AU - Leonardi, Francesco

AU - Negri, Francesca Virginia

AU - Anselmi, Elisa

AU - Losardo, Pier Luigi

AU - Roncoroni, Luigi

AU - Dell'Abate, Paolo

AU - Crafa, Pellegrino

AU - Cascinu, Stefano

AU - Ardizzoni, Andrea

PY - 2013/2

Y1 - 2013/2

N2 - Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5- fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC). Patients and Methods: Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m2 weekly and 5-fluorouracil 200 mg/m 2/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points. Results: Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7% (95% confidence interval=7.7-25.7%). After a median follow-up of 73.5 months, 23 patients (34.8%) had experienced relapse. Five-year actuarial RFS and OS rates were 64% and 73%, respectively. Five-year actuarial RFS was 91.7% in the ypCR group versus 57.8% in non-ypCR cases. Conclusion: Long-term local control and survival after this very well-tolerated regimen appear encouraging.

AB - Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5- fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC). Patients and Methods: Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m2 weekly and 5-fluorouracil 200 mg/m 2/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points. Results: Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7% (95% confidence interval=7.7-25.7%). After a median follow-up of 73.5 months, 23 patients (34.8%) had experienced relapse. Five-year actuarial RFS and OS rates were 64% and 73%, respectively. Five-year actuarial RFS was 91.7% in the ypCR group versus 57.8% in non-ypCR cases. Conclusion: Long-term local control and survival after this very well-tolerated regimen appear encouraging.

KW - Chemoradiation

KW - Colorectal adenocarcinoma

KW - Combined treatment

KW - Long-term outcome.

KW - Neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=84875900868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875900868&partnerID=8YFLogxK

M3 - Article

C2 - 23393374

AN - SCOPUS:84875900868

VL - 33

SP - 725

EP - 730

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -